Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma

BACKGROUND: Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma (HCC). In the present study, we evaluated the potential of early changes in the time-intensity curve (TIC) of arterial phase on contrast-enhanced ultrasound (CEUS) as early imagin...

全面介紹

Na minha lista:
書目詳細資料
發表在:World J Gastroenterol
Main Authors: Kuorda, Hidekatsu, Abe, Tamami, Fujiwara, Yudai, Okamoto, Takuya, Yonezawa, Miki, Sato, Hiroki, Endo, Kei, Oikawa, Takayoshi, Sawara, Kei, Takikawa, Yasuhiro
格式: Artigo
語言:Inglês
出版: Baishideng Publishing Group Inc 2019
主題:
Prospective Study
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6529888/
https://ncbi.nlm.nih.gov/pubmed/31148907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v25.i19.2365
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍